STOCK TITAN

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on commercializing dermatologic products, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on commercializing dermatologic products, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event will take place at the Metropolitan Club in New York, NY.

Key details of Biofrontera's presentation include:

  • Date: October 9, 2024
  • Time: 12:30 - 1:10 PM ET
  • Format: Live Presentation

The company has also made provisions for one-on-one meetings during the conference. Interested parties are advised to contact their Roth representative to schedule these meetings.

This presentation offers an opportunity for Biofrontera to showcase its developments in the dermatologic products sector to potential investors and industry professionals.

Loading...
Loading translation...
Argus Session date unavailable
-1.59% session move Open Argus
Details

News Market Reaction – BFRI

The recorded move for BFRI in the trading session of this news was -1.59%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York, NY.

Date: October 9, 2024
Time of Presentation: 12:30 - 1:10 PM ET
Format: Live Presentation
1x1 Meetings: Please contact your Roth representative

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.

Contacts Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com

SOURCE: Biofrontera Inc.



View the original press release on accesswire.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Biofrontera (BFRI) presenting at the ROTH Healthcare Opportunities Conference?

Biofrontera (BFRI) is scheduled to present at the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, from 12:30 to 1:10 PM ET.

Where will the 3rd Annual ROTH Healthcare Opportunities Conference be held?

The 3rd Annual ROTH Healthcare Opportunities Conference will be held at the Metropolitan Club in New York, NY.

What type of presentation will Biofrontera (BFRI) give at the ROTH conference?

Biofrontera (BFRI) will deliver a live presentation at the ROTH Healthcare Opportunities Conference.

Can investors meet with Biofrontera (BFRI) management at the ROTH conference?

Yes, one-on-one meetings with Biofrontera (BFRI) management are available. Interested parties should contact their Roth representative to schedule these meetings.

What is Biofrontera's (BFRI) primary business focus?

Biofrontera (BFRI) is a biopharmaceutical company specializing in the commercialization of dermatologic products.

Keep reading